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Abstract
The effects of controlled release on immune response to an immunomodulating peptide were
evaluated in a murine experimental autoimmune encephalomyelitis (EAE) model of multiple
sclerosis (MS). The peptide, Ac-PLP-BPI-NH2-2 (Ac-HSLGKWLGHPDKF-(AcpGAcpGAcp)2-
ITDGEATDSG-NH2; Ac = acetyl, Acp = aminocaproic acid) was designed to suppress T-cell
activation in response to PLP139–151, an antigenic peptide in MS. Poly-lactide-co-glycolide
(PLGA) microparticles containing Ac-PLP-BPI-NH2-2 (8±4 μm, 1.4±0.2% (w/w)) were prepared
by a powder-in oil-in water emulsion-solvent evaporation method, sterilized and administered
subcutaneously (s.c.) to SJL/J (H-2s) mice in which EAE had been induced by immunization with
PLP139–151. Treatment groups received Ac-PLP-BPI-NH2-2: (i) in solution by repeated i.v. or s.c.
injection, (ii) in solution co-administered with blank PLGA microparticles, (iii) in solution co-
administered with Ac-PLP-BPI-NH2-2 loaded microparticles, and (iv) as Ac-PLP-BPI-NH2-2
loaded microparticles. Administration of Ac-PLP-BPI-NH2-2 as an s.c. solution produced clinical
scores and maintenance of body weight comparable to i.v. solution, but with reduced overall
survival, presumably due to anaphylaxis. Administration as s.c. microparticles provided a
somewhat less effective reduction in symptoms but with no toxicity during treatment. Thus, the
results suggest that s.c. administration of Ac-PLP-BPI-NH2-2 microparticles can provide
pharmacological efficacy and reduction in dosing frequency without increased toxicity.
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1. Introduction
Autoimmune diseases such as Type 1 diabetes (T1D), multiple sclerosis (MS) and
rheumatoid arthritis (RA) are the result of an inappropriate immune response to endogenous
proteins or protein fragments, which serve as autoantigens. A critical component of this
response is the activation of T-cells that recognize a particular autoantigen. T-cell activation
© 2009 Elsevier B.V. All rights reserved.
*Corresponding author. Current address: Department of Industrial and Physical Pharmacy, Purdue University, 575 Stadium Mall
Drive, West Lafayette, IN 47907, United States. Tel.: +1 765 494 1450; fax: +1 765 494 6545. topp@purdue.edu (E.M. Topp).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.jconrel.2009.09.002.
NIH Public Access
Author Manuscript
J Control Release. Author manuscript; available in PMC 2014 January 27.
Published in final edited form as:













involves uptake of the antigenic protein by antigen presenting cells (APCs), which digest the
protein into peptide fragments. The fragments are then “presented” on the APC cell surface
bound to major histocompatibility complex (MHC) molecules. Binding of the T-cell
receptor to these MHC-bound peptides constitutes the primary signal (“Signal 1”) for T-cell
activation. A second, co-stimulatory signal (“Signal 2”) is also required, and involves higher
affinity binding of adhesion molecules that bridge the T-cell and APC. The clustering of
these two types of binding pairs and the subsequent translocation of the resulting
“immunological synapse” provide the signal for clonal expansion of the T-cell line,
ultimately leading to the autoimmune response [1-3].
Interfering with T-cell activation is a rational strategy for preventing and/or treating
autoimmune disease. One of us (TJS) has developed a class of novel bifunctional peptide
inhibitors (BPI) of T-cell activation, in which a peptide antigen involved in Signal-1
interactions is covalently linked to a second peptide that binds a Signal-2 adhesion molecule.
For example, a BPI for preventing T-cell activation in experimental autoimmune
encephalomyelitis (EAE), a murine model for MS, has the amino acid sequence
HSLGKWLGHPDKF-AcpGAcpGAcp-ITDGEATDSG. The peptide HSLGKWLGHPDKF
is an epitope of proteolipid protein (PLP139–151), an antigenic peptide in MS that is involved
in Signal-1 interactions. The peptide ITDGEATDSG binds intercellular adhesion molecule 1
(ICAM-1), blocking its binding with lymphocyte function-associated antigen 1 (LFA-1), a
Signal-2 interaction. The flexible linker AcpGAcpGAcp (Acp = aminocaproic acid)
connects the two peptides and provides appropriate spacing between them. The resulting
composite peptide, termed PLP-BPI, thus is designed to prevent T-cell activation by
interfering with both Signal-1 and Signal-2, and by preventing translocation of the
immunological synapse. Previous studies in an EAE mouse model have demonstrated that
PLP-BPI reduces disease incidence and symptom severity when given prophylactically [4],
and provides amelioration of symptoms when given therapeutically [5]. Specifically,
following immunization with PLP on Day 0 to induce EAE, administration of 100 nmol of
PLP-BPI on days 4, 7, 10 and 14 provided prophylactic suppression of EAE symptoms and
incidence [4]. Similarly, i.v. administration of 100 nmol of PLP-BPI on three consecutive
days following onset of symptoms showed therapeutic suppression of disease [5]. Promising
results have also been obtained with a BPI peptide in an NOD mouse model of T1D [6].
Thus, BPI peptides show promise as vaccines for preventing autoimmune disease. However,
unlike conventional vaccines which stimulate immune response to an administered antigen,
BPI peptides act by suppressing the immune response and promoting immunotolerance.
The need for repeated i.v. administration of PLP-BPI suggests that implantable or injectable
controlled release formulations may be warranted. Controlled release has long been used to
provide more convenient dosing for drugs that must be administered frequently in other
forms. A growing literature also suggests that controlled release of antigens from polymeric
materials may be particularly effective in promoting tolerance. The maintenance of
immunotolerance depends on antigen persistence in vivo, and is reversible if the antigen
source is removed [7], a finding that suggests that sustained release of antigen may be
effective in maintaining tolerance. Antigen release from polymeric materials has also been
shown to alter the Th1/Th2 balance, in some cases promoting the tolerogenic Th2-like
profile [8-10].
On the other hand, changes in the route of administration and the use of solid or particulate
dosage forms may stimulate the immune response. For example, the immune response to a
hepatitis B vaccine is influenced by the route of administration [11], and greater immune
responses are often observed following s.c. or i.m. administration than by the i.v. route
[12,13]. Micro- or nanoparticulate dosage forms may be selectively targeted to APCs
[14-16], so that the peptide drug is digested and presented by the MHC complex rather than
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released intact. Poly-lactide-co-glycolide (PLGA) and other polymers used in controlled
release devices may have adjuvant effects, recruiting APCs to the injection site and
stimulating their maturation [7,10]. Thus, controlled release formulations of PLP-BPI may
alter not only the frequency and route of administration, but also the extent and type of
therapeutic response, so that their performance is not easily predicted a priori.
This report describes the development and evaluation of a PLGA microparticle formulation
of Ac-PLP-BPI-NH2-2, a variant of PLP-BPI with the sequence Ac-HSLGKWLGHPDKF-
(AcpGAcpGAcp)2-ITDGEATDSGNH2 (Ac = acetyl, Acp = aminocaproic acid).
Microparticles were prepared by a suspension/solvent evaporation method and characterized
with regard to particle size and morphology, peptide loading, residual solvent content and in
vitro release rate. The Ac-PLP-BPI-NH2-2 loaded microparticles were then administered by
s.c. injection in an EAE mouse model, and compared to a variety of controls for their ability
to provide prophylactic suppression of disease symptoms. The results demonstrate that a
single s.c. microparticle dose provides disease suppression comparable to an identical dose
administered as four divided i.v. injections. The results also indicate an effect of route of
administration on the therapeutic response and toxicity of Ac-PLP-BPI-NH2-2.
2. Materials and methods
2.1. Materials
Poly(lactic- co-glycolic) acid was purchased from Durect Corporation (PLGA, 50:50,
inherent viscosity of 0.15–0.25 dL/g, MW ~10,000; Cupertino, CA), and polyvinyl alcohol
(PVA, MW 13,000–23,000, 98% hydrolyzed) was purchased from Sigma-Aldrich (St.
Louis, MO). All other chemicals or solvents are of analytical grade or better, and were used
as received.
2.2. Peptide synthesis
PLP and Ac-PLP-BPI-NH2-2 peptides were synthesized using 9-
fluorenylmethyloxycarbonyl- (FMOC) protected amino acid chemistry on appropriate
polyethylene glycol-polystyrene resins (Applied Biosystems, Foster City, CA) using an
automated peptide synthesis system (Pioneer; Perceptive Biosystems, Framingham, MA), as
described previously [4,5]. All amino acids and aminocaproic acid were supplied by Peptide
International (Kentucky, US). Cleavage of the peptides from the resin and removal of the
protecting groups from the side chain were carried out using trifluoroacetic acid with
scavengers. The crude peptides were purified by reversed-phase HPLC (Rainin, USA) using
a C18 column with a gradient of solvent A [95%/5%, H2O (0.1% trifluoroacetic acid)/
acetonitrile] and solvent B (100% acetonitrile). The purity of the peptide was analyzed by
analytical HPLC (Rainin, USA) using a C18 column. The mass of the synthesized peptide
was confirmed by matrix-assisted laser desorption ionization/time of flight (MALDI/TOF)
mass spectrometry; the theoretical molecular weight of the C-terminally acetylated peptide
is (i.e., Ac-PLP-BPI-NH2-2) is 3416.950.
2.3. Preparation of Ac-PLP-BPI-NH2-2 peptide-loaded microparticles
Ac-PLP-BPI-NH2-2 peptide-loaded microparticles were prepared by a powder-in oil-in
water emulsion-solvent evaporation method, using a method similar to that reported by Kim
and Burgess [17]. Briefly, 1.2 g of PLGA was added to 8 ml of methylene chloride
(CH2Cl2) and the polymer was allowed to dissolve completely. 200 mg of Ac-PLP-BPI-
NH2-2 peptide powder was then dispersed into the polymer solution and mixed using a
homogenizer (Power Gen 500, Fisher Scientific) for 2 min at 7000 rpm, followed by the
addition of 50 ml of a 1% PVA solution and homogenization for another 2 min at the same
speed. The final emulsion was poured into 150 ml of 1% PVA solution and stirred for 3 h to
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evaporate the solvent. The microparticles were then harvested by centrifugation and washed
three times with distilled water. The final dry microparticle product was obtained by
lyophilization (Virtis, Gardiner, NY, USA). After pre-freezing at −70 °C overnight, the
microparticles were lyophilized using the following protocol: −30 °C for 900 min, −15 °C
for 480 min, −5 °C for 240 min, 5 °C for 240 min, 15 °C for 120 min, and 25 °C for an
additional 120 min to complete dehydration. The products were then stored in sealed
containers at −20 °C until further use. This protocol was also used to prepare empty
microparticles, except that the polymer solution was directly emulsified with the 1% PVA
solution without the addition of the Ac-PLP-BPI-NH2-2 peptide.
2.4. Characterization of microparticles
Peptide-loaded and blank microparticles were characterized to determine surface
morphology, peptide content and residual methylene chloride content. In vitro peptide
release was also quantified to establish that the microparticle formulation provides
controlled release. Methods are described below.
2.4.1. Microparticle surface morphology and size distribution—The surface
morphology of microparticles was evaluated by scanning electron microscopy (SEM, D. Leo
Field Emission Scanning Electron Microscope, Hitachi S-4500, Tokyo, Japan) after sputter-
coating the samples with a 5 nm layer of Au/Pd. The microsphere size distribution was
determined from at least 500 particles per batch from SEM images using the public domain
image processing software, ImageJ [18].
2.4.2. Peptide content—A ~25 mg sample of microparticles was dissolved in 2 ml of
CH2Cl2. The peptide was extracted by addition of 3 ml of pH 13 solution (KCl/NaOH) three
times. The extracts were combined and assayed by HPLC using a C18 column with a
gradient of solvent A [95%/5%, H2O (0.1% trifluoroacetic acid)/acetonitrile] and solvent B
(100% acetonitrile) at a flow rate of 1 ml/min with UV detection at 215 nm. Under these
conditions, the retention time of the Ac-PLP-BPI-NH2-2 peptide is ~12.5 min and a
calibration prepared using standards of known concentration is linear in the concentration
range 10–100 μg/ml (r2≥0.995).
2.4.3. Residual CH2Cl2 content—Residual CH2Cl2 in the dry microparticles was
determined by gas chromatography/mass spectrometry (GC/MS). Data were collected on an
Agilent 6890N Gas Chromatrograph interfaced with a quadrupole mass analyzer (Quattro
Micro GC, Waters Corp., Milford, MA). A 5% phenyl, methyl silicone stationary phase
(HP-5MS) in a 15 m column with a 0.25″ ID was used. The carrier gas was He using
constant flow control set to 1.5 ml/min. To prepare samples for analysis, ~25 mg of
microparticles were dissolved in 0.5 ml of tetrahydrofuran (THF). 1.0 μl aliquots were then
injected into the injector port (240 °C) using a 25:1 split ratio. The GC thermal gradient was
set at an initial 35 °C with a 2 min hold, after which the temperature was increased 50 °C/
min to a final temperature of 180 °C and held for 2 min. Ionization was by electron impact at
70 eV. The analyzers were tuned to 0.6 full-width at the half-height (i.e., 0.6 FWHH) and
data were collected in the centroid mode. Signals were recorded as selected ion
chromatographs for m/z=71, 72 (THF) and m/z=84, 86 (CH2Cl2) using a target dwell time of
60 ms for m/z=84 and 10 ms for m/z=71, 72. Standard solutions of CH2Cl2 were prepared by
adding known amounts of CH2Cl2 to THF. Under these conditions, the calibration is linear
in the concentration range 300–1500 ppm (r2≥0.985).
2.4.4. In vitro peptide release—Approximately 30 mg of Ac-PLP-BPI-NH2-2 loaded
microparticles was weighed and placed in 1.5 ml of buffered medium (pH 7.4 PBS+0.05%
Tween-20) in capped vials. The vials were then placed in a 37±0.1 °C incubator and the
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rotation speed was set at 50 rpm. A sample (0.5 ml) was taken after centrifugation at the
various times up to 42 days. The volume removed was replaced with fresh medium, and the
amount of peptide released was determined by the HPLC method described above.
2.5. In vivo microparticle performance in an EAE mouse model
2.5.1. Mice—Female SJL/J (H-2s) mice were purchased from Charles River (Wilmington,
MA), and housed under specific pathogen-free conditions at an AAALAC-approved facility
at the University of Kansas. All protocols involving live mice were approved by the
University’s Institutional Animal Care and Use Committee and are in compliance with the
committee’s recommendations.
2.5.2. Induction of EAE and prophylactic suppression by Ac-PLP-BPI-NH2-2—
Five- to 7-week-old SJL/J female mice were randomly divided into six groups, with ten
mice in each group. All mice were immunized with PLP to induce EAE, as reported
previously [4,5]. Immunization involved s.c. administration of 200 μg of PLP139–151 in a 0.2
ml emulsion composed of equal volumes of phosphate-buffered saline (PBS) and complete
Freund’s adjuvant (CFA) containing killed Mycobacterium tuberculosis strain H37RA (final
H37RA concentration 4 mg/ml; Difco, Detroit, MI). The PLP139–151/CFA solution was
administered to four separate regions above the shoulder and on the flanks, with 50 μl
injected at each site. In addition, 200 ng of pertussis toxin (PT; List Biological Laboratories
Inc., Campbell, CA) was injected i.p. on the day of immunization (Day 0) and 2 days after
immunization (Day 2). PT facilitates the development of EAE in this model, an effect that
has been attributed to PT-induced activation of APCs [19].
The ability of various formulations of Ac-PLP-BPI-NH2-2 to suppress the development and
progression of EAE was investigated using six treatment groups (Table 1, Phase I).
Following initial immunization on Day 0 and pertussis toxin boosting on Day 2, treatments
were administered on Days 4, 7, 10 and 14 (Table 1). Mice in Group 1 received four equal
doses of 100 μL of PBS by i.v. injection, and served as a negative control. Mice in Group 2
received four i.v. injections of 100 nmol Ac-PLP-BPI-NH2-2 peptide in PBS, with a dose
and route of administration used in previous studies of this peptide [4,5]. Mice in Group 3
received four s.c. injections of 100 nmol Ac-PLP-BPI-NH2-2 peptide. Comparison of Group
3 results with those of Group 2 is expected to provide information on route of administration
effects. Mice in Group 4 received four s.c. injections of 100 nmol of Ac-PLP-BPI-NH2-2
peptide, with concomitant administration of 25 mg of blank PLGA microparticles.
Comparison of results for Groups 3 and 4 is expected to identify possible adjuvant effects of
blank microparticles. Mice in Groups 5 and 6 received microparticles loaded with the Ac-
PLP-BPI-NH2-2 peptide. Those in Group 5 received an initial 100 nmol solution dose on
Day 4, followed by a 300 nmol microparticle dose (~75 mg microparticles containing 300
nm Ac-PLP-BPI-NH2-2) on Day 7. Mice in Group 6 received a 400 nmol dose of peptide in
microparticle form (~100 mg microparticles) on Day 4. Comparison of results for Groups 5
and 6 with solution treatments (Groups 2–4) addresses the ability of controlled peptide
release to achieve prophylactic effects comparable to repeated solution injections. All six of
these treatment groups received a total of 400 nmol Ac-PLP-BPI-NH2-2 peptide/mouse, and
all microparticle formulations (i.e., Groups 4–6) were sterilized by overnight exposure to
u.v. radiation in a clean bench prior to administration. Follow-up studies were conducted at a
lower dose of 300 nmol Ac-PLP-BPI-NH2-2 peptide/mouse (Groups 7–9, Table 1).
Disease progression was evaluated blindly by the same observer, as reported previously
[4,5], according to the following clinical scoring scale: 0 — no clinical signs of disease; 1 —
tail weakness or limp tail; 2 — paraparesis (weakness or incomplete paralysis of one or two
hind limbs); 3 — paraplegia (complete paralysis of two hind limbs); 4 — paraplegia with
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forelimb weakness or paralysis; and 5 — moribund. Mice were euthanized once they were
found to be moribund. Body weight was measured daily.
2.5.3. Induction and monitoring of anaphylaxis—In addition to their beneficial
therapeutic effects, antigen-derived peptides such as Ac-PLP-BPI-NH2-2 have the potential
to induce fatal anaphylaxis, particularly on repeated injection. To compare the anaphylactic
response to Ac-PLP-BPI-NH2-2 administered in different forms (solution vs. microparticle),
by different routes (i.v. and s.c.) and with different dosing frequency, an “anaphylaxis dose”
of 100 nmol was administered at the end of the treatment period to challenge the immune
system by repeated exposure to a previously administered antigen. At Day 45, animals in
Groups 2–6 (Table 1) received 100 nmol Ac-PLP-BPI-NH2-2 peptide/mouse, while those in
Group 1 received 100 nmol PLP peptide/mouse. For each group, the route of administration
of the anaphylactic dose was the same as that used for earlier treatment. The incidence of
anaphylactic response is reported as the percentage of mice in each group that died within 30
min after the anaphylactic dose. Characteristic signs of immediate hypersensitivity (i.e.,
piloerection; prostration; erythema of the tail, ears, and footpads; shallow breathing; and
lethargy) observed within a few minutes after the anaphylactic dose were also recorded.
3. Results
3.1. Microparticle properties and in vitro release
PLGA microparticles containing Ac-PLP-BPI-NH2-2 were successfully prepared by the
powder-in oil-in water solvent evaporation method. This method produced Ac-PLP-BPI-
NH2-2 loaded microparticles with a mean size of 8±4 μm, as shown by SEM micrographs
and corresponding size distributions (Fig. 1A). Blank PLGA microparticles were roughly
twice this size, with a mean size of 16±5 μm (Fig. 1B). Both peptide-loaded and blank
microparticles were spherical with a smooth surface, though occasional pores in the surface
of the peptide-loaded microparticles may be the result of peptide leaching during fabrication
(Fig. 1A). Peptide leaching, perhaps followed by particle contraction, may also contribute to
the smaller size of the peptide-loaded vs. blank microparticles. Both types of microparticles
are less than 30 μm, and thus are expected to pass freely through a 20 gauge needle and are
suitable for s.c. injection. The peptide content of the Ac-PLP-BPI-NH2-2 loaded
microparticles was 1.4±0.2% (w/w) and the peptide encapsulation efficiency was 8.2±1.2%
(n=3,±S.D.). This low encapsulation efficiency and loading suggest poor retention of the
hydrophilic Ac-PLP-BPI-NH2-2 peptide on exposure to aqueous washing solutions during
microparticle fabrication. Residual CH2Cl2 in the microparticle formulation, as determined
by GC/MS, was 580±30 ppm (n=3,±S.D.), below the recommended ICH limit of 600 ppm
[20].
The in vitro release of Ac-PLP-BPI-NH2-2 from peptide-loaded microparticles shows an
initial burst of ~15%, sustained release of ~1% per day through Day 21, followed by more
rapid release during Days 21 to 44 (Fig. 2). This triphasic release profile is typical for PLGA
microspheres [21,22]. The initial burst is widely believed to be caused by rapid release of
drug from the particle surface [23], while the subsequent period of slow release is thought to
reflect release by diffusion through the polymer matrix. The final, more rapid release phase
is typically attributed to extensive degradation of the polymer matrix and release by erosion.
For our purposes, the in vitro release profile demonstrates that the microparticle formulation
is effective in providing sustained release over a period of more than forty days in buffered
solution. It is therefore reasonable to expect that this formulation will also provide sustained
release when injected s.c., and will generate a release profile distinct from s.c. injection of
the peptide in solution.
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3.2. In vivo microparticle performance in an EAE mouse model
Mice were immunized on Day 0 to induce disease, then treated with various Ac-PLP-BPI-
NH2-2 or control formulations over a two-week period (Table 1; Phase I). Figs. 3 and 4
show body weight and clinical scores for mice treated prophylactically for suppression of
EAE symptoms; a statistical comparison of the treatment groups at each time point is
available online as Supplementary Material. Deaths were observed both during treatment
and on administration of the anaphylactic dose; Table 2 presents percent survival values for
each group at the end of the treatment period (Day 14) and following the anaphylactic dose
(Day 45). Group 1 received repeated i.v. injections of PBS (Table 1), and serves as an
untreated control. Mice in Group 1 showed a nearly 20% decrease in weight during Days
10–12 (Fig. 3), with corresponding worsening of neurological symptoms as indicated by
increasing clinical scores (Fig. 4). Both body weight and clinical scores show improvements
following Day 15, an observation consistent with the typical relapse/remission pattern of the
EAE model. There were no fatalities in Group 1 at the end of the treatment period (Day 14,
Table 2).
Only 20% of mice in Group 1 survived the anaphylactic dose, however (Day 45, Table 2),
suggesting a high potential for anaphylactic toxicity on repeated i.v. administration of the
PLP peptide. Mice in Group 2 received repeated i.v. injections of Ac-PLP-BPI-NH2-2 in
aqueous solution (Table 1). As in previous studies of PLP-BPI [4,5], these mice showed no
appreciable weight loss (Fig. 3) and had no clinical signs of disease (score = 0; Fig. 4),
confirming that repeated i.v. administration of Ac-PLP-BPI-NH2-2 provides effective
suppression of EAE symptoms. 90% of mice in Group 2 survived at the end of the treatment
period (Day 14, Table 2) and 30% survived the analphylactic dose (Day 45, Table 2),
suggesting that i.v. Ac-PLP-BPI-NH2-2 has a potential to induce anaphylaxis comparable to
PLP. Mice in Group 3 received repeated s.c. injections of Ac-PLP-BPI-NH2-2 in aqueous
solution (Table 1), a treatment protocol that differs from that for Group 2 only in the route of
administration. Body weights and clinical scores in Groups 2 and 3 were similar, suggesting
similar therapeutic effects by the two routes (Figs. 3 and 4). However, survival was
markedly reduced in Group 3, suggesting increased toxicity and/or a reduction in the
effective dose range when Ac-PLP-BPI-NH2-2 is administered s.c. rather than i.v. (Group 3
vs. Group 2; Table 2). Mice in Group 4 received repeated s.c. injections of Ac-PLP-BPI-
NH2-2 in solution, together with injections of blank PLGA microparticles (Table 1). Body
weights and clinical scores for Group 4 were equivalent or superior to those for Groups 2
and 3, indicating that blank PLGA microparticles have no appreciable effects on treatment.
Survival of mice in Group 4 was comparable to that for Group 3, again suggesting route of
administration effects on Ac-PLP-BPI-NH2-2 toxicity and/or dose range (Groups 3 and 4 vs.
Group 2; Table 2) and the absence of microparticle effects. Mice in Group 5 received an s.c.
injection of Ac-PLP-BPI-NH2-2 in solution on Day 4, followed by an s.c. injection of
microparticles on Day 7 (Table 1). Body weights (Fig. 3) and clinical scores (Fig. 4) were
somewhat lower for mice in Group 5 than for those in groups receiving Ac-PLP-BPI-NH2-2
in solution only (Groups 2–4, Table 1), though clearly better than the untreated control
(Group 1, Table 1). Interestingly, 100% of mice in Group 5 survived the treatment period
(Day 14, Table 2), suggesting that the toxicities associated with repeated s.c. injection of
Ac-PLP-BPI-NH2-2 in solution (Groups 3,4; Table 2) are reduced by slower and/or
incomplete release from the microparticle dosage form. Sterlization by u.v. irradiation may
contribute to incomplete release, an effect observed previously for TGFß3-loaded PLGA
microspheres [24]. Only 10% of Group 5 mice survived the anaphylactic dose, however
(Table 2), suggesting that the potential for anaphylactic toxicity remains. Mice in Group 6
received a single dose of Ac-PLP-BPI-NH2-2 loaded microparticles (Table 1). Body weights
for mice in Group 6 were comparable to those of Group 5 (Fig. 3) and clinical scores
somewhat superior, particularly late in the treatment period (Fig. 4). Survival percentages
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for Group 6 were identical to those of Group 5 (Table 2), again suggesting that Ac-PLP-
BPI-NH2-2 toxicity is reduced by slow release and/or lower dose from the microparticle
dosage form.
To probe the effects of dose, a second phase of animal studies was conducted in which a
reduced dose of Ac-PLP-BPI-NH2-2 (300 nm) was administered in solution by either the i.v.
or s.c. route (Phase II, Table 1). Effective suppression of EAE disease progression, as
indicated by stable body weight (Fig. 5A) and low clinical score (Fig. 5B), was achieved
with both i.v. and s.c. administration of three 100 nm doses of Ac-PLP-BPI-NH2-2, rather
than the four 100 nm doses used in Phase I. In addition, there was no evidence of fatal
toxicity during the treatment period, with 100% survival of mice receiving either the 300 nm
i.v. dose (Group 8; Tables 1, 2) or the 300 nm s.c. dose (Group 9; Tables 1, 2). Reponses to
the anaphylactic dose (Day 45, Table 2) showed somewhat greater fatalities in mice
receiving the s.c. dose (Group 9, Table 2) than the i.v. dose (Group 8, Table 2), consistent
with the results at higher dose in Phase I.
4. Discussion
MS involves the activation of CD4+ T-cells leading to inflammation and the destruction of
myelin in the central nervous system. Current drug treatments for MS include corticosteroids
to control inflammation; interferons (e.g., Betaseron) as general immunodulators; Tysabri®
(natalizumab), a monoclonal antibody to α4 integrin thought to prevent the entry of
activated T-cells into the CNS [25,26]; and Copaxone® (glatiramer acetate), a peptide
copolymer related to the myelin basic protein (MBP) that induces Th2 regulatory cells
[27,28]. These drugs offer considerable benefits to MS patients, but carry the risk of
interference with normal immune function. For example, Tysabri® was temporarily
withdrawn from the market after patients in clinical trials were infected with the JC virus.
This viral infection causes progressive multifocal leukoencephalopathy (PML), a brain-
wasting disease that can produce dementia, paralysis and even death [26,29,30], and that
occurs most often in immunocompromised patients. The PLP-BPI peptide and its derivatives
(e.g., Ac-PLP-BPI-NH2-2) being developed by co-author Siahaan and his group [4,5] and
related inhibitors of T-cell activation reported by other groups [31-33] offer the promise of
specific modulation of the pathological autoimmune response while preserving the immune
system’s ability to respond to foreign pathogens. PLP-BPI peptides are hypothesized to
induce immunotolerance in an antigen-specific manner by preventing the translocation of
Signal-1 and Signal-2, which form the immunological synapse at the interface of the T-cell
and the APC. The goal of treatment with PLP-BPI peptides thus is the induction of tolerance
to PLP139–151, an MS associated antigen, by preventing the activation of T-cells that
respond to it.
The method of delivery of PLP-BPI peptides may be important for balancing their efficacy
and toxicity in vivo. In the studies reported here, we have compared the effects of three
routes of administration (i.v. solution, s.c. solution, and s.c. microparticle) on the EAE
suppressive activity of Ac-PLP-BPI-NH2-2 by measuring body weight, clinical score and
survival. Interestingly, the results demonstrate that the in vivo activity of Ac-PLP-BPI-
NH2-2 is influenced by route of administration. Specifically, s.c. solution administration of
Ac-PLP-BPI-NH2-2 provides symptom amelioration comparable to i.v. solution
administration (Fig. 3), but with greater incidence of toxicity (Table 2). In contrast, s.c.
administration of Ac-PLP-BPI-NH2-2 in microparticle form provides slightly lower activity
in reducing disease symptoms (Fig. 3), but does not show any toxicity during treatment
(Table 2). All routes of administration show low survival rates on repeat challenge with the
antigen as the anaphylactic dose (Day 45, Table 2). The results thus suggest that s.c.
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administration of PLP-BPI peptides in microparticle form can provide pharmacological
efficacy and reduction in dosing frequency without increased toxicity.
It should be noted that the microparticles used in these studies were sterilized by exposure to
u.v. radiation, a method less commonly used than exposure to ethylene oxide or γ-
irradiation. The u.v. method was the only method readily available to us and is known to be
effective for inactivating bacteria and viruses on surfaces. However, lack of complete
sterility and u.v.-induced changes in the PLGA and/or PLP-BPI cannot be ruled out. Moioli
et al. observed incomplete release from TGFß3-loaded PLGA microspheres following u.v.
sterilization [24]. If the PLP-BPI peptide is similarly affected, this could contribute to the
reduced toxicity of the microparticle forms.
Controlled and/or sustained release of antigens from polymeric materials have been
investigated for altering the immune response and inducing immunotolerance by modulating
Th1/Th2 balance, in some cases promoting the tolerogenic Th2-like profile [8-10]. It has
been suggested that the maintenance of immunotolerance depends on antigen persistence in
vivo, and can be reversed if the antigen source is removed [7]. Particulate delivery systems
have been used for selective targeting to APCs, so that incorporated antigens are more
effectively presented by MHC molecules and therefore more likely to be immunogenic. For
example, in cancer-immunotherapy, a ten-fold lower dose was required when tetanus-toxoid
(TT) was delivered in PLGA microspheres compared to solution delivery, suggesting
antigen targeted APC delivery by microspheres [34]. Although there is growing evidence
that PLGA and other polymeric materials have inherent adjuvant effects for stimulating
immune response [7,10], the effect of particle size, morphology, surface chemistry and site
of administration influence have not been fully elucidated [8-10]. Previous reports have
documented uptake of PLGA microparticles in the 0.5 to 10 μm size range by dendritic cells
[14,34,35] and macrophages [36]. This provides opportunities to study the effects of particle
characteristics and delivery sites during antigen delivery on the immune response and its
modulation.
In the studies reported here, Ac-PLP-BPI-NH2-2 was loaded into microparticles (<10 μm,
Fig. 1) for delivery either via uptake by APCs or by controlled release of Ac-PLP-BPI-
NH2-2 to extracellular receptor of the APCs. The therapeutic response to the microparticle
dosage forms is consistent with sustained extracellular release of Ac-PLP-BPI-NH2-2 or,
alternatively, to APC uptake without digestion of the Ac-PLP-BPI-NH2-2 peptide; the
former is deemed more likely. Controlled release from these ~10 μm particles rather than
APC uptake and digestion may be due to the large total mass of microparticles administered,
which may agglomerate to form a depot in situ. Similarly, the data are not consistent with a
marked adjuvant effect of the microparticles, since the therapeutic and toxic effects of s.c.
injection of Ac-PLP-BPI-NH2-2 in solution were not affected by co-injection of
microparticles (Table 1, Groups 3 and 4; Fig. 3, Table 2). That survival rates during
treatment with the microparticle formulations are higher than for s.c. solutions (Groups 3,4
vs. Groups 5,6; Day 14, Table 2) suggests that sustained delivery of Ac-PLP-BPI-NH2-2 has
promoted tolerance, while low survival following anaphylactic challenge on Day 45 is
consistent with the overwhelming of tolerance to induce anaphylaxis. However, differences
in total dose delivered by microparticle and solution forms cannot be ruled out. Additional
studies to fully define the dose/response profile for Ac-PLP-BPI-NH2-2, including the
effects of route of administration on the therapeutic window, are in progress.
Like MS, the EAE mouse model is an autoimmune inflammatory and demyelinating disease
of the central nervous system. Local cytokine production varies significantly during EAE
disease progression, and increases in discrete sets of cytokines are associated with the acute
response and the recovery/chronic phase of the disease [37]. In EAE mice treated with PLP-
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BPI by i.v. injection, levels of CD4+CD25+TGF-β+, CD4+CD25+IL-4+ and
CD4+CD25+IL-10+ T-cells were significantly greater than those in untreated controls in the
lymphocyte population recovered from isolated spleens [4]. Elevated levels of IL-17 have
been detected in the cerebrospinal fluid and in brain lesions of MS patients, and the IL-17
level is highly correlated with disease activity [38-40]. In mice receiving Ac-PLP-BPI-
NH2-2 as an i.v. solution, IL-17 levels were significantly lower than those in PBS-treated
controls [5]. In the current studies, the observed differences in therapeutic and anaphylactic
responses following Ac-PLP-BPI-NH2-2 administration by different routes (s.c. vs. i.v.
injection) and with different dosing frequency (microparticle vs. solution) suggest that
cytokine profiles may be influenced by these dosing factors, although further investigation is
needed.
5. Conclusions
The results presented here demonstrate that administration of Ac-PLP-BPI-NH2-2 by any of
three different routes (i.e., i.v. solution, s.c. solution, and s.c. microparticle) produces
significant suppression of disease onset in EAE mice relative to controls receiving PBS
alone. Administration of Ac-PLP-BPI-NH2-2 as an s.c. solution produced clinical scores and
maintenance of body weight comparable to the i.v. solution, but with reduced overall
survival, while administration as s.c. microparticles provided a somewhat less effective
reduction in symptoms but with no toxicity during treatment. The results thus suggest that
s.c. administration of Ac-PLP-BPI-NH2-2 in microparticle form can provide
pharmacological efficacy and reduction in dosing frequency without increased toxicity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SEM micrographs of microparticles (A,C) and corresponding particle size distributions
(B,D). (A) SEM micrograph of Ac-PLP-BPI-NH2-2 loaded microparticles; scale bar is 10
μm. (B) Particle size distribution of Ac-PLP-BPI-NH2-2 loaded microparticles. Mean size =
8 ± 4 μm; median size = 9 μm. (C) SEM micrograph of blank microparticles, scale bar is 20
μm. (D) Particle size distribution of blank microparticles. Mean size = 16 ± 5 μm; median
size = 18 μm.
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In vitro release of Ac-PLP-BPI-NH2-2 from PLGA microparticles (pH 7.4 PBS + 0.05%
Tween-20, 37 °C, 50 rpm stirring). n = 3 ± S.D.
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Body weight change as percentage of initial weight in EAE mice receiving Ac-PLP-BPI-
NH2-2 microparticle formulations or controls at 400 nmol total dose. Treatment groups
correspond to Groups 1–6 in Table 1: Group 1 (■); Group 2 (□); Group 3 (Δ); Group 4 (▼);
Group 5 (▷); and Group 6 (●). n = 10 ± S.D. See Supplementary Material, Table S1, for
statistical comparison of treatment and control groups on each day.
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Clinical scores for EAE mice receiving Ac-PLP-BPI-NH2-2 microparticle formulations or
controls at 400 nmol total dose. Treatment groups correspond to Groups 1–6 (Phase I) in
Table 1: Group 1 (■); Group 2 (□); Group 3 (Δ); Group 4 (▼); Group 5 (▷); and Group 6
(●). n = 10 ± S.D. See Supplementary Material, Table S2, for statistical comparison of
treatment and control groups on each day.
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Body weight change (A) and clinical scores (B) for EAE mice receiving Ac-PLP-BPI-
NH2-2 solutions or controls at 300 nmol total dose. Treatment groups correspond to Groups
7–9 (Phase II) in Table 1: Group 7 (■); Group 8 (□); and Group 9 (Δ). n = 10±S.D. See
Supplementary Material, Tables S3 and S4, for statistical comparison of treatment and
control groups on each day.
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Table 2
Percent survival of mice in treatment groups 1–9 (see Table 1).
Group
Treatment Day
Day 0 Day 14 Day 45
Phase I
1 100 100 20
2 100 90 30
3 100 60 0
4 100 60 0
5 100 100 10
6 100 100 10
Phase II
7 100 90 10
8 100 100 20
9 100 100 0
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